by Jinghong Chen

For all Parkinson’s disease drugs — except Inbrija — on the market, more than half of covered lives are under the preferred tier/preferred with prior authorization or step therapy and covered tier/covered with PA/ST. The graphic below shows how Parkinson’s disease medications are covered among commercial health plans, health exchange programs and Medicare and Medicaid programs under the pharmacy benefit.

NOTE: Under the pharmacy benefit, the number of total covered lives is 211.7 million. For Azilect and Neupro, about 0.04% and 0.01% of covered lives are under the generic (preferred) tier.

SOURCE: Managed Markets Insight & Technology, LLC database as of September 2019.